HomeCompareGRPH vs EPRT

GRPH vs EPRT: Dividend Comparison 2026

GRPH yields 64.78% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRPH wins by $757.9K in total portfolio value
10 years
GRPH
GRPH
● Live price
64.78%
Share price
$3.18
Annual div
$2.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$821.3K
Annual income
$203,467.89
Full GRPH calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GRPH vs EPRT

📍 GRPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRPHEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRPH + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRPH pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRPH
Annual income on $10K today (after 15% tax)
$5,506.29/yr
After 10yr DRIP, annual income (after tax)
$172,947.71/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, GRPH beats the other by $162,033.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRPH + EPRT for your $10,000?

GRPH: 50%EPRT: 50%
100% EPRT50/50100% GRPH
Portfolio after 10yr
$442.4K
Annual income
$108,154.31/yr
Blended yield
24.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GRPH
Analyst Ratings
7
Hold
1
Sell
Consensus: Hold
Price Target
$4.00
+25.8% upside vs current
Range: $2.00 — $7.00
Altman Z
5.3
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRPH buys
0
EPRT buys
0
No recent congressional trades found for GRPH or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRPHEPRT
Forward yield64.78%3.92%
Annual dividend / share$2.06$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$821.3K$63.4K
Annual income after 10y$203,467.89$12,840.73
Total dividends collected$690.7K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$4.00$35.50

Year-by-year: GRPH vs EPRT ($10,000, DRIP)

YearGRPH PortfolioGRPH Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$17,178$6,477.99$11,205$505.18+$6.0KGRPH
2$28,780$10,399.89$12,672$682.46+$16.1KGRPH
3$47,079$16,284.27$14,490$930.48+$32.6KGRPH
4$75,270$24,895.34$16,786$1,282.69+$58.5KGRPH
5$117,738$37,198.68$19,753$1,791.56+$98.0KGRPH
6$180,359$54,379.70$23,677$2,541.64+$156.7KGRPH
7$270,837$77,853.00$29,008$3,672.99+$241.8KGRPH
8$399,056$109,260.19$36,463$5,425.08+$362.6KGRPH
9$577,444$150,453.99$47,238$8,221.57+$530.2KGRPH
10$821,333$203,467.89$63,385$12,840.73+$757.9KGRPH

GRPH vs EPRT: Complete Analysis 2026

GRPHStock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full GRPH Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GRPH vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRPH vs SCHDGRPH vs JEPIGRPH vs OGRPH vs KOGRPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.